What is the 13F Pro Quality Score for ACXP?

13F Pro ranks Acurx Pharmaceuticals, Inc. (ACXP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ACXP's current score at https://13fpro.ai/company/ACXP (free sign-up required for the full ranking).

Where does 13F Pro source ACXP data?

All Acurx Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Acurx Pharmaceuticals, Inc. files with the SEC under CIK 1736243. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ACXP in?

Acurx Pharmaceuticals, Inc. (ACXP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ACXP research updated on 13F Pro?

ACXP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Acurx Pharmaceuticals, Inc.(ACXP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1736243 ACXP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ACXP Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Acurx Pharmaceuticals, Inc. (ACXP), a Healthcare sector company. ACXP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ACXP by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. ACXP trades on the Nasdaq exchange and files with the SEC under CIK 1736243. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ACXP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Acurx Pharmaceuticals, Inc. directly from SEC EDGAR.

✦

Fun facts about Acurx Pharmaceuticals, Inc.

Quirks, history, and lore behind ACXP — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · focused on developing treatments for serious bacterial infections.
2
The Numbers
A true micro-cap with minimal revenue, burning cash as it funds clinical trials — the kind of company where the pipeline IS the balance sheet.
3
The History
Founded in the early 2010s and headquartered in Staten Island, New York — not exactly the biotech zip code you'd expect.
4
The Secret
Its lead program targets Clostridioides difficile (C. diff) infections, a nasty hospital-acquired bug that kills tens of thousands of Americans annually and is notoriously hard to treat.
5
The Lore
Its novel antibiotic candidate works by blocking bacterial DNA polymerase IIIC — a mechanism so targeted it leaves your healthy gut bacteria largely unbothered, which is the whole point.
6
The Giveaway
Its lead drug ibezapolstat is designed to knock out C. diff without torching the microbiome — a small Staten Island bet on a big antibiotic blind spot.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-2.3M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+43.5% YoY

$-8.0MFY 2025

FY22 $-12.1MFY23 $-14.6MFY24 $-14.1MFY25 $-8.0M

Operating Income

+42.7% YoY

$-8.1MFY 2025

FY22 —FY23 —FY24 $-14.1MFY25 $-8.1M

EPS (Diluted)

+69.5% YoY

$-5.32FY 2025

FY22 $-1.12FY23 $-1.15FY24 $-17.45FY25 $-5.32

Total Assets

+99.3% YoY

$7.7MFY 2025

FY22 $9.4MFY23 $7.7MFY24 $3.9MFY25 $7.7M

Op. Cash Flow

+34.6% YoY

$-6.8MFY 2025

FY22 $-7.5MFY23 $-9.8MFY24 $-10.4MFY25 $-6.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-8.0M +43.5%	$-14.1M +3.3%	$-14.6M -20.5%	$-12.1M +5.1%	$-12.7M -177.1%	$-4.6M
Operating Income	$-8.1M +42.7%	$-14.1M	—	—	—	—
EPS (Diluted)	$-5.32 +69.5%	$-17.45 -1417.4%	$-1.15 -2.7%	$-1.12 +24.8%	$-1.49 -101.4%	$-0.74
Total Assets	$7.7M +99.3%	$3.9M -50.0%	$7.7M -17.8%	$9.4M -29.3%	$13.3M +311.1%	$3.2M
Operating Cash Flow	$-6.8M +34.6%	$-10.4M -5.9%	$-9.8M -29.9%	$-7.5M -50.4%	$-5.0M -49.6%	$-3.4M

Get alerted when ACXP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Acurx Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ACXP

VANGUARD CAPITAL MANAGEMENT LLC
$48.2K31,099 sh
GEODE CAPITAL MANAGEMENT, LLC
$40.9K26,411 sh
VANGUARD FIDUCIARY TRUST CO
$25.1K16,205 sh
JANE STREET GROUP, LLC
$24.4K15,727 sh
Prospect Financial Services LLC
$21.4K13,785 sh
MORGAN STANLEY
$11.6K7,500 sh
Integrated Wealth Concepts LLC
$7.3K4,729 sh
Tower Research Capital LLC (TRC)
$4.3K2,744 sh
WELLS FARGO & COMPANY/MN
$3.6K2,300 sh
Westside Investment Management, Inc.
$2.6K1,650 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$48.2K	31,099
GEODE CAPITAL MANAGEMENT, LLC	$40.9K	26,411
VANGUARD FIDUCIARY TRUST CO	$25.1K	16,205
JANE STREET GROUP, LLC	$24.4K	15,727
Prospect Financial Services LLC	$21.4K	13,785
MORGAN STANLEY	$11.6K	7,500
Integrated Wealth Concepts LLC	$7.3K	4,729
Tower Research Capital LLC (TRC)	$4.3K	2,744
WELLS FARGO & COMPANY/MN	$3.6K	2,300
Westside Investment Management, Inc.	$2.6K	1,650

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ACXP on your watchlist

Track score changes the day Acurx Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ACXP a good stock to buy?

13F Pro's AI-powered analysis of Acurx Pharmaceuticals, Inc. (ACXP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ACXP are available on the ACXP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ACXP is classified as a small company.

Which hedge funds own ACXP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ACXP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Acurx Pharmaceuticals, Inc.'s investment landscape.